Bal Pharma Ltd Stock Price Today (NSE: BALPHARMA)
Fundamental Score
Bal Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bal Pharma Ltd share price today is ₹60.42, down 1.51% on NSE/BSE as of 30 March 2026. Bal Pharma Ltd (BALPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹118.87 (Cr). The 52-week high for BALPHARMA share price is ₹128.74 and the 52-week low is ₹65.00. At a P/E ratio of 17.43x, BALPHARMA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.66% and a debt-to-equity ratio of 1.98.
Bal Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Bal Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Bal Pharma Share Price Analysis: A Growth Strategist's Perspective
In the dynamic pharmaceutical sector, where innovation and regulatory compliance are paramount, access to consistent earnings is crucial for achieving and sustaining industry dominance. This analysis focuses on the "Bal Pharma share price" (₹69.93 as of recent data) and its financial health, within the context of its peers. The company's current Price-to-Earnings (PE) ratio stands at 17.43, which provides a basis for comparison with other players in the market.
A critical factor in evaluating a pharmaceutical company's long-term viability is its Return on Capital Employed (ROCE). Bal Pharma Ltd. exhibits a ROCE of 10.1%. This figure reveals how efficiently the company generates profits from its capital investments. A higher ROCE usually indicates a stronger competitive advantage or "moat." However, compared to industry leaders, 10.1% suggests there is room for improvement to strengthen its market position and deter competitors. For example, a pharmaceutical with stronger brand recall can command higher profit margins, which subsequently improves ROCE. The 10.1% ROCE influences the capital allocation decisions of Bal Pharma, and is key in evaluating management's performance.
When assessing competitors, management quality needs to be evaluated. Considering
Mankind Pharma Ltd, a key differentiator could be the management's ability to execute strategic acquisitions or effectively manage research and development pipelines. While this analysis does not provide a direct comparison of management quality, investors should consider this facet when evaluating Bal Pharma Ltd. against its peers like Smruthi Organics Ltd. and Balaxi Pharmaceuticals Ltd.. Thorough due diligence on leadership is necessary when considering long-term investment.This analysis is part of a comprehensive 80-parameter fundamental audit conducted and verified by Sweta Mishra. It is purely observational and does not constitute financial advice. The analysis should be used for informational purposes only and is intended to help understand the company's financial position from a Growth Strategist's perspective.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bal Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 17.43 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (12.11% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (20.34% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.95% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹34.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (50.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (9.66%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Profit Decline Concern (-31.73%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.98)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.24x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.23%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Bal Pharma Ltd Financial Statements
Comprehensive financial data for Bal Pharma Ltd including income statement, balance sheet and cash flow
About BALPHARMA (Bal Pharma Ltd)
Bal Pharma Ltd is a dynamic pharmaceutical entity focused on the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. The company dist...inguishes itself through its dedication to innovation and its commitment to providing accessible healthcare solutions across multiple therapeutic areas. Bal Pharma operates with a multifaceted approach, encompassing the production of both finished formulations and active pharmaceutical ingredients (APIs), ensuring a vertically integrated supply chain and greater control over product quality. With a strong presence in both domestic and international markets, Bal Pharma seeks to address unmet medical needs and improve patient outcomes through the consistent delivery of high-quality, affordable medications. Bal Pharma's product portfolio caters to a wide spectrum of medical conditions, reflecting its understanding of evolving healthcare demands. Their offerings include prescription medications targeting various ailments, generic alternatives providing cost-effective treatment options, over-the-counter (OTC) products for self-care, and essential intravenous infusion products. The company also specializes in bulk drug manufacturing, supplying vital ingredients to other pharmaceutical companies. Through strategic brand development, Bal Pharma offers specialized products focused on key therapeutic areas such as anti-infectives, pain relief, respiratory health, and women's health, with established brands like Aziwin and Monogesic Plus Gel. Moreover, Bal Pharma is actively engaged in addressing the growing global prevalence of diabetes. The company's diabetic care product range reflects its commitment to improving the lives of individuals managing this chronic condition. By focusing on research and development, Bal Pharma continuously strives to introduce innovative and effective pharmaceutical solutions that enhance treatment outcomes and improve the overall quality of life for patients. Ultimately, Bal Pharma aims to be a reliable partner in healthcare, providing a comprehensive range of pharmaceutical products that meet the diverse needs of patients and healthcare professionals alike.
Company Details
Key Leadership
Corporate Events
BALPHARMA Share Price: Frequently Asked Questions
What is the current share price of Bal Pharma Ltd (BALPHARMA)?
As of 30 Mar 2026, 12:02 pm IST, Bal Pharma Ltd share price is ₹60.42. The BALPHARMA stock has a market capitalisation of ₹118.87 (Cr) on NSE/BSE.
Is BALPHARMA share price Overvalued or Undervalued?
BALPHARMA share price is currently trading at a P/E ratio of 17.43x, compared to the industry average of 31.77x. Based on this relative valuation, the Bal Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of BALPHARMA share price?
The 52-week high of BALPHARMA share price is ₹128.74 and the 52-week low is ₹65.00. These values are updated daily from NSE/BSE price data.
What factors affect the Bal Pharma Ltd share price?
Key factors influencing BALPHARMA share price include quarterly earnings growth (Sales Growth: 0.45%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Bal Pharma Ltd a good stock for long-term investment?
Bal Pharma Ltd shows a 5-year Profit Growth of 20.95% and an ROE of 9.66%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.98 before investing in BALPHARMA shares.
How does Bal Pharma Ltd compare with its industry peers?
Bal Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare BALPHARMA share price P/E of 17.43x and ROE of 9.66% against the industry averages to determine competitive standing.
What is the P/E ratio of BALPHARMA and what does it mean?
BALPHARMA share price has a P/E ratio of 17.43x compared to the industry average of 31.77x. Investors pay ₹17 for every ₹1 of annual earnings.
How is BALPHARMA performing according to Bull Run's analysis?
BALPHARMA has a Bull Run fundamental score of 41.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BALPHARMA belong to?
BALPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Bal Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for BALPHARMA?
BALPHARMA has an ROE of 9.66%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Bal Pharma Ltd generates profits from shareholders capital.
How is BALPHARMA debt-to-equity ratio and what does it indicate?
BALPHARMA has a debt-to-equity ratio of 1.98, which indicates high leverage that increases financial risk.
What is BALPHARMA dividend yield and is it a good dividend stock?
BALPHARMA offers a dividend yield of 1.59%, meaning you receive ₹1.59 annual dividend for every ₹100 invested in Bal Pharma Ltd shares.
How has BALPHARMA share price grown over the past 5 years?
BALPHARMA has achieved 5-year growth rates of: Sales Growth 12.11%, Profit Growth 20.95%, and EPS Growth 20.34%.
What is the promoter holding in BALPHARMA and why does it matter?
Promoters hold 50.86% of BALPHARMA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Bal Pharma Ltd.
What is BALPHARMA market capitalisation category?
BALPHARMA has a market capitalisation of ₹119 crores, placing it in the Small-cap category.
How volatile is BALPHARMA stock?
BALPHARMA has a beta of N/A. A beta > 1 suggests the Bal Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BALPHARMA operating profit margin trend?
BALPHARMA has a 5-year average Operating Profit Margin (OPM) of 9.10%, indicating the company's operational efficiency.
How is BALPHARMA quarterly performance?
Recent quarterly performance shows Bal Pharma Ltd YoY Sales Growth of 0.45% and YoY Profit Growth of -31.73%.
What is the institutional holding pattern in BALPHARMA?
BALPHARMA has FII holding of 0.23% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Bal Pharma Ltd stock.